These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37629728)

  • 1. Metabolic Associated Fatty Liver Disease (MAFLD) and COVID-19 Infection: An Independent Predictor of Poor Disease Outcome?
    Milivojević V; Bogdanović J; Babić I; Todorović N; Ranković I
    Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629728
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease.
    Jeeyavudeen MS; Chaudhari R; Pappachan JM; Fouda S
    World J Gastroenterol; 2023 Jan; 29(3):487-502. PubMed ID: 36688018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management.
    Xu Y; Yang X; Bian H; Xia M
    Lipids Health Dis; 2021 Oct; 20(1):126. PubMed ID: 34602072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019.
    Gao F; Zheng KI; Yan HD; Sun QF; Pan KH; Wang TY; Chen YP; Targher G; Byrne CD; George J; Zheng MH
    Front Endocrinol (Lausanne); 2021; 12():604100. PubMed ID: 33763027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Non-Alcoholic Fatty Liver Disease and Metabolic-Associated Fatty Liver Disease with COVID-19-Related Intensive Care Unit Outcomes: A Systematic Review and Meta-Analysis.
    Jagirdhar GSK; Pattnaik H; Banga A; Qasba RK; Rama K; Reddy ST; Bucharles ACF; Kashyap R; Elmati PR; Bansal V; Bains Y; DaCosta T; Surani S
    Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512051
    [No Abstract]   [Full Text] [Related]  

  • 6. Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight.
    Vasques-Monteiro IML; Souza-Mello V
    World J Gastroenterol; 2021 Apr; 27(16):1738-1750. PubMed ID: 33967554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Dysfunction-Associated Fatty Liver Disease in Newly Diagnosed, Treatment-Naive Hypertensive Patients and Its Association with Cardiorenal Risk Markers.
    Theofilis P; Vordoni A; Tsimihodimos V; Kalaitzidis RG
    High Blood Press Cardiovasc Prev; 2023 Jan; 30(1):63-72. PubMed ID: 36626077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19, adaptative immune response and metabolic-associated liver disease.
    Miele L; Napodano C; Cesario A; De Magistris A; Pocino K; Basile U; Rapaccini GL; Gasbarrini A; Grieco A
    Liver Int; 2021 Nov; 41(11):2560-2577. PubMed ID: 34555255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 Pandemic: Insights into Interactions between SARS-CoV-2 Infection and MAFLD.
    Chen H; Chen Q
    Int J Biol Sci; 2022; 18(12):4756-4767. PubMed ID: 35874945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence.
    Buchynskyi M; Kamyshna I; Oksenych V; Zavidniuk N; Kamyshnyi A
    Viruses; 2023 Apr; 15(5):. PubMed ID: 37243158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19.
    Campos-Murguía A; Román-Calleja BM; González-Regueiro JA; Hurtado-Díaz-de-León I; Solís-Ortega AA; Flores-García NC; García-Juárez I; Ruiz-Margáin A; Macías-Rodríguez RU
    World J Gastroenterol; 2021 Sep; 27(33):5502-5519. PubMed ID: 34588748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Association of Metabolic-Associated Fatty Liver Disease with Clinical Outcomes of COVID-19: A Systematic Review and Meta-Analysis.
    Hayat U; Ashfaq MZ; Johnson L; Ford R; Wuthnow C; Kadado K; El Jurdi K; Okut H; Kilgore WR; Assi M; Siddiqui AA
    Kans J Med; 2022; 15():241-246. PubMed ID: 35899064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis.
    Pan L; Huang P; Xie X; Xu J; Guo D; Jiang Y
    Dig Liver Dis; 2021 Feb; 53(2):153-157. PubMed ID: 33011088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Associated Fatty Liver Disease Is Associated With an Increased Risk of Severe COVID-19: A Systematic Review With Meta-Analysis.
    Hegyi PJ; Váncsa S; Ocskay K; Dembrovszky F; Kiss S; Farkas N; Erőss B; Szakács Z; Hegyi P; Pár G
    Front Med (Lausanne); 2021; 8():626425. PubMed ID: 33777974
    [No Abstract]   [Full Text] [Related]  

  • 15. The Impact of Increased Fib-4 Score in Patients with Type II Diabetes Mellitus on Covid-19 Disease Prognosis.
    Calapod OP; Marin AM; Onisai M; Tribus LC; Pop CS; Fierbinteanu-Braticevici C
    Medicina (Kaunas); 2021 Apr; 57(5):. PubMed ID: 33946377
    [No Abstract]   [Full Text] [Related]  

  • 16. Adipose tissue dysfunction and MAFLD in obesity on the scene of COVID-19.
    Cordeiro A; Ribamar A; Ramalho A
    Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101807. PubMed ID: 34543756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perirenal Fat Thickness is Associated with Metabolic Dysfunction-Associated Fatty Liver Disease in Type 2 Diabetes Mellitus.
    Yang J; Li CW; Zhang JR; Qiu H; Guo XL; Wang W
    Diabetes Metab Syndr Obes; 2023; 16():1953-1965. PubMed ID: 37405319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: A data-driven cluster analysis with international validation.
    Ye J; Zhuang X; Li X; Gong X; Sun Y; Wang W; Feng S; Wu T; Zhong B
    Metabolism; 2022 Nov; 136():155294. PubMed ID: 35995280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease with advanced fibrosis in the death and intubation of patients hospitalized with coronavirus disease 2019.
    Vázquez-Medina MU; Cerda-Reyes E; Galeana-Pavón A; López-Luna CE; Ramírez-Portillo PM; Ibañez-Cervantes G; Torres-Vázquez J; Vargas-De-León C
    Hepatol Commun; 2022 Aug; 6(8):2000-2010. PubMed ID: 35438253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes.
    Samimi S; Rajabzadeh S; Rabizadeh S; Nakhjavani M; Nakhaei P; Avanaki FA; Esteghamati A
    Eur J Med Res; 2022 Jul; 27(1):112. PubMed ID: 35818084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.